Methods: Eight groups of nude mice subcutaneouslygrafted with the human TT medullary
thyroid cancer cell line were injected once tumor volume reached about 200 mm3. Two …

This study compared the toxicity and efficacy of 131I-labeled bivalent hapten pretargeted by
anti-carcinoembryonic antigen (CEA)/anti-Nα-(diethylenetriamine-N, N, N′, N ″-tetraacetic …

The purpose of this study was to evaluate biodistributions and absorbed doses of anti-
carcinoembryonic antigen (CEA)/anti-diethylenetriamine pentaacetic acid (DTPA)-indium …

A significant antitumor effect was previously observed with radioimmunotherapy using anti–
carcinoembryonic antigen 131I-F6 monoclonal antibody in medullary thyroid cancer …

The purpose of this study was to estimate the dose delivered to tumor targets and normal
tissues after two-step injection of an anti-CEA/anti-DTPA-ln (F6-734) bispecific antibody and …

The toxicity and therapeutic efficacy of escalating doses of anti-carcinoembryonic antigen×
anti-Nα-(diethylenetriamine-N, N, N′, N ″-tetraacetic acid)-In bispecific monoclonal …

Safety, targeting, and antitumor efficacy of pretargeted radioimmunotherapy using anti-
carcinoembryonic antigen (CEA) hMN-14× m734 bispecific antibody (BsmAb) and 131I-di …

A significant antitumor effect associated with moderate toxicity was obtained previously with
anticarcinoembryonic antigen× antidiethylene-triaminepentaacetic acid (DTPA)-indium F6 …

Radioimmunotherapy of Medullary Thyroid Cancer with Iodine-131-Labeled Anti-CEA
Antibodies Page 1 Radioimmunotherapy of Medullary Thyroid Cancer with Iodine-131-Labeled …

We have developed a pretargeting strategy, called the Affinity Enhancement System (AES),
which uses bispecific antibodies (BsF (ab′) 2) to target radiolabeled bivalent haptens to …